WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2000062780) USE OF GLUCOSYLCERAMIDE SYNTHESIS INHIBITORS IN THERAPY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2000/062780    International Application No.:    PCT/GB2000/001563
Publication Date: 26.10.2000 International Filing Date: 20.04.2000
Chapter 2 Demand Filed:    10.11.2000    
IPC:
A61K 31/00 (2006.01), A61K 31/445 (2006.01), A61K 31/5375 (2006.01), A61K 31/70 (2006.01), A61K 45/06 (2006.01)
Applicants: OXFORD GLYCOSCIENCES (UK) LIMITED [GB/GB]; The Forum, 86 Milton Park, Abingdon, Oxon 0X14 4RY (GB) (For All Designated States Except US).
WALKLEY, Steven [US/US]; (US) (For US Only).
HOLT, Gordon, D. [US/US]; (US) (For US Only)
Inventors: WALKLEY, Steven; (US).
HOLT, Gordon, D.; (US)
Agent: LEE, Nicholas, John; Kilburn & Strode, 20 Red Lion Street, London WC1R 4PJ (GB)
Priority Data:
9909064.9 20.04.1999 GB
Title (EN) USE OF GLUCOSYLCERAMIDE SYNTHESIS INHIBITORS IN THERAPY
(FR) UTILISATION THERAPEUTIQUE D'INHIBITEURS DE SYNTHESE DE GLUCOSYLCERAMIDES
Abstract: front page image
(EN)The present invention relates to the treatment of conditions such as Niemann-Pick C storage disease, Alzheimer's disease, epilepsy, stroke and Parkinson's disease, and in particular to the use of inhibitors of glucosylceramide synthesis in such treatment. Preferred inhibitors of glucosylceramide synthesis are imino sugar-structured, and include N-butyldeoxynojirimycin (NB-DNJ), N-butyldeoxygalactonojirimycin (NB-DGJ) and N-nonyldeoxynojirimycin (NN-DNJ).
(FR)L'invention concerne le traitement de maladies telles que la maladie de Niemann-Pick de type C, la maladie d'Alzheimer, les attaques d'apoplexie et la maladie de Parkinson, et en particulier l'utilisation d'inhibiteurs de la synthèse du glucosylcéramide dans un tel traitement. Les inhibiteurs préférés de la synthèse du glucosylcéramide présentent une structure iminosucre et comprennent la N-butyldéoxynojirimycine (NB-DNJ), la N-butyldéoxygalactonojirimycine (NB-DGJ) et la N-nonyldéoxynojirimycine (NN-DNJ).
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)